Funded Biotechnology Startups in Houston
Houston's biotechnology funding activity across these 18 companies stretches from February 2021 through September 2025, with disclosed round sizes ranging…
Houston's biotechnology funding activity across these 18 companies stretches from February 2021 through September 2025, with disclosed round sizes ranging from $300K (Pulmotect, June 2023) to $350M (Solugen's Series C, September 2021). The set is weighted toward therapeutics — Coya Therapeutics, Tvardi Therapeutics, Iterion Therapeutics, Salarius Pharmaceuticals, and CNS Pharmaceutical all appear — but includes industrial biotech in Solugen, which raised $214M in a June 2024 follow-on after its Series C, and medical-device crossover in BiVACOR, which closed a $13M round in February 2024.
Ten of the 18 rows carry a "Series Unknown" label, reflecting how frequently Houston biotech raises appear outside a cleanly labeled stage. AlloVir is the only post-IPO issuer visible, having raised $127M in July 2022. At the early stage, Cellvie's $5M Seed in September 2025 is the most recent entry in the set, while Alleviant Medical's $90M round in January 2025 represents the largest raise with a 2025 date.
Most recent rounds
18 shownRelated listings
Frequently asked
What are the largest recent rounds among Houston biotech companies in this data?
Solugen leads with a $350M Series C in September 2021 and a separate $214M round in June 2024. AlloVir raised $127M via Post-IPO Equity in July 2022, and Alleviant Medical closed a $90M round in January 2025. Below those, the next largest disclosed amounts are Tvardi Therapeutics at $72M (June 2021) and Iterion Therapeutics at $17M (February 2021).
Which Houston biotech company has raised multiple rounds in this dataset?
Solugen is the only company appearing more than once across these 18 rows, with a $350M Series C in September 2021 followed by a $214M round in June 2024, totaling $564M in disclosed funding across the two entries.
What round types are most common in this Houston biotech snapshot?
Ten of the 18 rows carry a "Series Unknown" label, making it the dominant classification and limiting stage-by-stage analysis. Seed rounds appear three times (Cellvie, K2bio, Western Chemical Consulting), while the remaining entries include one Series B (Iterion Therapeutics), one Series C (Solugen), one Post-IPO Equity (AlloVir), and two rows with no round type listed (Tvardi Therapeutics, Stellanova Therapeutics).
How recent is the funding activity shown, and are there 2025 raises?
The most recent round is Cellvie's $5M Seed in September 2025. CNS Pharmaceutical closed a $5M round in May 2025 and Alleviant Medical raised $90M in January 2025, making three companies with rounds dated to 2025 in this set. The oldest entry is Iterion Therapeutics' $17M Series B from February 2021.
Are any Houston biotech companies here operating outside drug development?
Solugen focuses on industrial and green chemistry biotech rather than therapeutics, and is the largest fundraiser in the set across two visible rounds. BiVACOR sits at the biotech-medical device intersection, having raised $13M in February 2024 for its cardiac pump program.
What is the deal size range across these Houston biotech rounds?
Disclosed round sizes span from $300K (Pulmotect, June 2023) and $620K (K2bio, August 2023) at the low end to $350M (Solugen, September 2021) at the high end. One round from Western Chemical Consulting (July 2023) is listed as undisclosed, and two rounds have no amount recorded.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.